奥美沙坦对慢性心力衰竭患者血清Galectin-3 水平的影响

目的：探讨奥美沙坦对慢性心力衰竭患者血清半乳凝集素-3（Galectin-3）水平的影响。方法：入选慢性心力衰竭患者100 例， 随机分为2 组，对照组和奥美沙坦治疗组，每组50 例，持续治疗3 月。其中对照组男32 例，女18 例，平均年龄（53.2± 11.8）；奥美 沙坦治疗组，男35 例，女15 例，平均年龄为（52.6± 13.2）岁。超声心动图评估治疗前后心功能，采用双抗体酶联免疫吸附(ELISA) 法测定血清Galectin-3 和N 末端B 型钠尿肽（NT-proBNP）水平。结果：对照组治疗和奥美沙坦治疗均可以改善慢性心力衰竭患 者的射血分数（EF），降低NT-proBNP和Galectin-3 的浓度。其中，对比对照组患者，奥美沙坦治疗的患者心功能改善的程度更明 显，并伴有血清Galectin-3 的明显下降，差异具有统计学意义，P<0.05。Pearson 相关分析结果显示，慢性心力衰竭患者血清 Galectin-3 水平与心功能指标EF和NT-proBNP均相关，相关系数分别为-0.563和0.605，统计学有意义（P<0.05）。结论：奥美沙坦 治疗能有效降低慢性心力衰竭患者血清Galectin-3 水平和改善心功能。

The Effects of Olmesartan on the Serum level of Galectin-3 in Patients with Chronic Heart Failure

Objective:To explore the effects of olmesartan on the serum level of galectin-3 in patients with chronic heart failure.Methods:One hundred chronic heart failure patients were included in the present study. The patients were randomly divided into two groups, including the control group and olmesartan treatment group. There were fifty patients in each group. 32 males and 18 females whose average age was 52.6± 13.2 years were in the control group, while 35 males and 15 females with an average age of 52.6± 13.2 years were included in the olmesartan treatment group. The cardiac function was assessed by echocardiography. The serum level of galectin-3 and NT-proBNP were measured by enzyme-linked immunosorbent assay.Results:The ejection fraction of patients was improved in both groups. The serumlevels of NT-proBNP and galectin-3 of the patients were decreased both in the control group and the olmesartan treatment group. Compared with the control group, the degrees of improvement of cardiac function were larger, and the serum levels of galectin-3 were decreased more obviously in patients of the olmesartan group. The serum level of galectin-3 were correlated with EF and NT-proBNP (r=-0.563 and 0.605 respectively, P<0.05) in chronic heart failure patients.Conclusion:Olmesartan treatment is effective in decreasing the serum level of galectin-3 and improving the the cardiac function in patients with chronic heart failure.